Development of RNA trans-splicing ribozyme Editing Technology
"Will grow into an Innovative Therapeutics Development Company"

Rznomics, a new drug development company based on RNA trans-splicing ribozyme editing technology, announced on the 24th that it has been selected as a new company for the 'Deep tech Incubator Project for Startup (DIPS) 1000+'.

The 'Deep tech Incubator Project for Startup 1000+' project is led by the Korea Institute of Startup & Entrepreneurship Development under the Ministry of SMEs and Startups. From last year until 2027, the project aims to select and support startups with unique technological superiority in ten key future-leading fields such a bio, healthcare, system semiconductors, and next-generation nuclear power, to foster them into global unicorns.

Through this project selection, Rznomics will receive direct business funding of up to 600 million KRW over the next three years, along with linked support for policy funds, guarantees, exports, and specialized support tailored to industry characteristics.

Seong-wook Lee, CEO of Rznomics, said, "We are delighted that the selection for the DIPS 1000+ project has once again recognized the innovation and growth potential of Rznomics’ technology. With the support from this selection, we will focus on ongoing clinical trials and technology commercialization to grow into a leading company in developing innovative therapeutics for various rate and intractable diseases.